

ANNEX  
2

**Country  
profiles**  
FOR  
22 HIGH-BURDEN  
COUNTRIES



# Afghanistan ■ Population 2014 32 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	14 (10–18)	44 (32–57)
Mortality (HIV+TB only)	0.087 (0.072–0.1)	0.28 (0.23–0.33)
Prevalence (includes HIV+TB)	110 (56–180)	340 (178–555)
Incidence (includes HIV+TB)	60 (53–67)	189 (167–212)
Incidence (HIV+TB only)	0.32 (0.25–0.4)	1 (0.8–1.3)
Case detection, all forms (%)	53 (47–60)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	3.2 (2.3–4.1)	17 (11–23)
MDR-TB cases among notified pulmonary TB cases	750 (540–960)	360 (240–490)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	14 737	1 209
Pulmonary, clinically diagnosed	8 573	
Extrapulmonary	7 227	
<b>Total new and relapse</b>	<b>31 746</b>	
Previously treated, excluding relapses	966	
<b>Total cases notified</b>	<b>32 712</b>	

Among 30 537 new cases:

4 454 (15%) cases aged under 15 years; male:female ratio: 0.7

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	2 (<1%)	184 (8%)	186
Laboratory-confirmed RR-/MDR-TB cases			88
Patients started on MDR-TB treatment <sup>c</sup>			88

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	10 443	(32)
HIV-positive TB patients	4	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB	142	
HIV-positive people provided with IPT	7	

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(88)	30 507
Previously treated cases, excluding relapse, registered in 2013	(74)	1 115
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(71)	38
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	2.3
Culture (per 5 million population)	0.5
Drug susceptibility testing (per 5 million population)	0
Sites performing Xpert MTB/RIF	1
Is second-line drug susceptibility testing available?	Yes, outside country

## Financing TB control 2015







National TB programme budget (US\$ millions)	15
% Funded domestically	6%
% Funded internationally	67%
% Unfunded	27%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Bangladesh ■ Population 2014 159 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	81 (59–110)	51 (37–68)
Mortality (HIV+TB only)	0.18 (0.14–0.22)	0.11 (0.09–0.14)
Prevalence (includes HIV+TB)	640 (340–1 000)	404 (211–659)
Incidence (includes HIV+TB)	360 (320–410)	227 (200–256)
Incidence (HIV+TB only)	0.57 (0.45–0.71)	0.36 (0.28–0.45)
Case detection, all forms (%)	53 (47–60)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.7–2.5)	29 (24–34)
MDR-TB cases among notified pulmonary TB cases	2 100 (1 000–3 700)	2 700 (2 200–3 200)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	106 767	2 989
Pulmonary, clinically diagnosed	42 832	863
Extrapulmonary	37 406	309

<b>Total new and relapse</b>	<b>191 166</b>
Previously treated, excluding relapses	5 631
<b>Total cases notified</b>	<b>196 797</b>

Among 187 005 new cases:

6 262 (3%) cases aged under 15 years; male:female ratio: 1.5

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	12 573 (12%)	4 959 (51%)	43 360
Laboratory-confirmed RR-/MDR-TB cases			994
Patients started on MDR-TB treatment <sup>c</sup>			945

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	1 110	(<1)
HIV-positive TB patients	45	(4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	45	(100)
HIV-positive TB patients on antiretroviral therapy (ART)	45	(100)
HIV-positive people screened for TB	726	
HIV-positive people provided with IPT	0	

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(93)	184 077
Previously treated cases, excluding relapse, registered in 2013	(86)	6 327
HIV-positive TB cases, all types, registered in 2013	(75)	68
RR-/MDR-TB cases started on second-line treatment in 2012	(72)	505
XDR-TB cases started on second-line treatment in 2012	(25)	4

## Laboratories 2014

Smear (per 100 000 population)	0.7
Culture (per 5 million population)	<0.1
Drug susceptibility testing (per 5 million population)	<0.1
Sites performing Xpert MTB/RIF	38
Is second-line drug susceptibility testing available?	Yes, in and outside country

## Financing TB control 2015







National TB programme budget (US\$ millions)	48
% Funded domestically	<1%
% Funded internationally	70%
% Unfunded	30%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals. A joint reassessment of estimates of TB disease burden will be undertaken following completion of the national TB prevalence survey.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Brazil ■ Population 2014 **206 million**

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	5.3 (4.9–5.7)	2.6 (2.4–2.7)
Mortality (HIV+TB only)	2.4 (1.8–3.2)	1.2 (0.87–1.6)
Prevalence (includes HIV+TB)	110 (51–180)	52 (25–89)
Incidence (includes HIV+TB)	90 (86–95)	44 (42–46)
Incidence (HIV+TB only)	16 (14–17)	7.6 (6.9–8.4)
Case detection, all forms (%)	82 (78–86)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (1–1.8)	7.5 (5.7–9.9)
MDR-TB cases among notified pulmonary TB cases	820 (590–1 100)	950 (720–1 300)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	41 120	3 602
Pulmonary, clinically diagnosed	17 801	1 488
Extrapulmonary	9 479	480

<b>Total new and relapse</b>	<b>73 970</b>
Previously treated, excluding relapses	7 542
<b>Total cases notified</b>	<b>81 512</b>

Among 73 970 new and relapse cases:  
2 368 (3%) cases aged under 15 years; male:female ratio: 2.1

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			15 344
Laboratory-confirmed RR-/MDR-TB cases			702
Patients started on MDR-TB treatment <sup>c</sup>			702

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	56 981	(70)
HIV-positive TB patients	9 578	(17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB	37 540	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(72)	76 543
Previously treated cases, excluding relapse, registered in 2013	(38)	6 945
HIV-positive TB cases, all types, registered in 2013	(46)	9 460
RR-/MDR-TB cases started on second-line treatment in 2012	(51)	825
XDR-TB cases started on second-line treatment in 2012	(25)	24

## Laboratories 2014

Smear (per 100 000 population)	1.6
Culture (per 5 million population)	7.9
Drug susceptibility testing (per 5 million population)	0.6
Sites performing Xpert MTB/RIF	48
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	77
% Funded domestically	72%
% Funded internationally	<1%
% Unfunded	27%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	8.9 (6.3–12)	58 (41–78)
Mortality (HIV+TB only)	0.82 (0.63–1)	5.3 (4.1–6.7)
Prevalence (includes HIV+TB)	100 (87–120)	668 (565–780)
Incidence (includes HIV+TB)	60 (54–66)	390 (353–428)
Incidence (HIV+TB only)	1.8 (1.6–2)	12 (10–13)
Case detection, all forms (%)	72 (66–80)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.7–2.5)	11 (4–22)
MDR-TB cases among notified pulmonary TB cases	330 (160–590)	200 (73–400)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	12 168	445
Pulmonary, clinically diagnosed	11 286	709
Extrapulmonary	18 310	141

<b>Total new and relapse</b>	<b>43 059</b>
Previously treated, excluding relapses	679
<b>Total cases notified</b>	<b>43 738</b>

Among 43 059 new and relapse cases:  
12 050 (28%) cases aged under 15 years; male:female ratio: 1.2

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	646 (5%)	1 329 (67%)	1 975
Laboratory-confirmed RR-/MDR-TB cases			110
Patients started on MDR-TB treatment <sup>c</sup>			110

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	35 635	(81)
HIV-positive TB patients	953	(3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	938	(98)
HIV-positive TB patients on antiretroviral therapy (ART)	938	(98)
HIV-positive people screened for TB	3 504	
HIV-positive people provided with IPT	901	

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(93)	35 536
Previously treated cases, excluding relapse, registered in 2013	(90)	1 701
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(79)	110
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	1.4
Culture (per 5 million population)	1.3
Drug susceptibility testing (per 5 million population)	1.0
Sites performing Xpert MTB/RIF	17
Is second-line drug susceptibility testing available?	No

## Financing TB control 2015







National TB programme budget (US\$ millions)	31
% Funded domestically	12%
% Funded internationally	47%
% Unfunded	42%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# China ■ Population 2014 1 369 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	38 (37–40)	2.8 (2.7–2.9)
Mortality (HIV+TB only)	0.7 (0.53–0.9)	0.05 (0.04–0.07)
Prevalence (includes HIV+TB)	1 200 (1 100–1 400)	89 (78–102)
Incidence (includes HIV+TB)	930 (860–1 000)	68 (63–73)
Incidence (HIV+TB only)	13 (11–16)	0.98 (0.79–1.2)
Case detection, all forms (%)	88 (82–95)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	5.7 (4.5–7)	26 (22–30)
MDR-TB cases among notified pulmonary TB cases	43 000 (34 000–53 000)	8 200 (6 900–9 500)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	235 704	25 125
Pulmonary, clinically diagnosed	526 106	
Extrapulmonary	32 348	

<b>Total new and relapse</b>	<b>819 283</b>
Previously treated, excluding relapses	6 872
<b>Total cases notified</b>	<b>826 155</b>

Among 819 283 new and relapse cases:  
4 164 (<1%) cases aged under 15 years; male:female ratio: 2.3

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	45 664 (19%)	17 210 (54%)	62 874
Laboratory-confirmed RR-/MDR-TB cases			5 807
Patients started on MDR-TB treatment <sup>c</sup>			2 846

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	343 515	(42)
HIV-positive TB patients	5 309	(2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	3 675	(69)
HIV-positive people screened for TB	423 254	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(95)	841 999
Previously treated cases, excluding relapse, registered in 2013	(90)	7 847
HIV-positive TB cases, all types, registered in 2013	(82)	4 649
RR-/MDR-TB cases started on second-line treatment in 2012	(42)	1 906
XDR-TB cases started on second-line treatment in 2012	(13)	115

## Laboratories 2014

Smear (per 100 000 population)	0.2
Culture (per 5 million population)	6.7
Drug susceptibility testing (per 5 million population)	1.5
Sites performing Xpert MTB/RIF	654
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	340
% Funded domestically	90%
% Funded internationally	2%
% Unfunded	8%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Democratic Republic of the Congo ■ Population 2014 **75 million**

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	52 (38–68)	69 (50–90)
Mortality (HIV+TB only)	6.3 (5–7.7)	8.4 (6.7–10)
Prevalence (includes HIV+TB)	400 (210–640)	532 (282–859)
Incidence (includes HIV+TB)	240 (220–270)	325 (295–356)
Incidence (HIV+TB only)	34 (27–42)	45 (36–56)
Case detection, all forms (%)	48 (43–52)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.2 (0.3–4.1)	11 (6.2–16)
MDR-TB cases among notified pulmonary TB cases	2 000 (270–3 700)	790 (450–1 100)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	75 631	4 298
Pulmonary, clinically diagnosed	13 494	1 892
Extrapulmonary	19 566	914

## Total new and relapse 115 795

Previously treated, excluding relapses 1 099

## Total cases notified 116 894

Among 75 631 new cases:

3 438 (5%) cases aged under 15 years; male:female ratio: 1.3

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	545 (<1%)	6 135 (75%)	6 817
Laboratory-confirmed RR-/MDR-TB cases			442
Patients started on MDR-TB treatment <sup>c</sup>			436

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	53 285	(46)
HIV-positive TB patients	7 206	(14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	5 671	(79)
HIV-positive TB patients on antiretroviral therapy (ART)	4 799	(67)
HIV-positive people screened for TB	33 743	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(87)	112 439
Previously treated cases registered in 2013	(66)	1 164
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(64)	134
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	2.1
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	39
Is second-line drug susceptibility testing available?	Yes, in and outside country

## Financing TB control 2015







National TB programme budget (US\$ millions)	55
% Funded domestically	5%
% Funded internationally	50%
% Unfunded	44%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.





# Ethiopia ■ Population 2014 97 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	32 (22–43)	33 (23–44)
Mortality (HIV+TB only)	5.5 (4.4–6.8)	5.7 (4.6–7)
Prevalence (includes HIV+TB)	190 (160–240)	200 (161–243)
Incidence (includes HIV+TB)	200 (160–240)	207 (168–250)
Incidence (HIV+TB only)	19 (15–23)	19 (15–24)
Case detection, all forms (%)	60 (49–73)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.6 (0.86–2.8)	12 (5.6–21)
MDR-TB cases among notified pulmonary TB cases	1 300 (700–2 300)	

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	40 087	
Pulmonary, clinically diagnosed	41 575	
Extrapulmonary	37 930	

## Total new and relapse 119 592

Previously treated, excluding relapses

## Total cases notified 119 592

Among 119 592 new cases:

15 917 (13%) cases aged under 15 years; male:female ratio: 1.2

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	2 405 (6%)	7 682	10 151
Laboratory-confirmed RR-/MDR-TB cases			503
Patients started on MDR-TB treatment <sup>c</sup>			557

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	89 320	(75)
HIV-positive TB patients	8 670	(10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) <sup>d</sup>		
HIV-positive TB patients on antiretroviral therapy (ART) <sup>d</sup>	3 396	(39)
HIV-positive people screened for TB	341 534	
HIV-positive people provided with IPT	10 385	

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(89)	43 86
Previously treated cases registered in 2013		
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(83)	271
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	3.1
Culture (per 5 million population)	0.4
Drug susceptibility testing (per 5 million population)	0.4
Sites performing Xpert MTB/RIF	28
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015

National TB programme budget (US\$ millions)	82
% Funded domestically	11%
% Funded internationally	42%
% Unfunded	47%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

<sup>d</sup> ART and IPT data were missing for 3 of Ethiopia's 11 regions, which in previous years had accounted for about one third of the national totals. In the 8 regions that reported data, 65% of HIV-positive TB patients were on ART.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	220 (150–350)	17 (12–27)
Mortality (HIV+TB only)	31 (25–38)	2.4 (2–2.9)
Prevalence (includes HIV+TB)	2 500 (1 700–3 500)	195 (131–271)
Incidence (includes HIV+TB)	2 200 (2 000–2 300)	167 (156–179)
Incidence (HIV+TB only)	110 (96–120)	8.3 (7.4–9.3)
Case detection, all forms (%)	74 (70–80)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.2 (1.9–2.6)	15 (11–19)
MDR-TB cases among notified pulmonary TB cases	24 000 (21 000–29 000)	47 000 (35 000–59 000)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	754 268	124 679
Pulmonary, clinically diagnosed	343 032	112 066
Extrapulmonary	275 502	

## Total new and relapse 1 609 547

Previously treated, excluding relapses 74 368

## Total cases notified 1 683 915

Among 1 609 547 new and relapse cases:  
95 709 (6%) cases aged under 15 years; male:female ratio: 1.9

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	12 795 (2%)	214 209 (69%)	255 897
Laboratory-confirmed RR-/MDR-TB cases			25 748
Patients started on MDR-TB treatment <sup>c</sup>			24 073

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	1 034 712	(61)
HIV-positive TB patients	44 171	(4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	41 066	(93)
HIV-positive TB patients on antiretroviral therapy (ART)	39 800	(90)
HIV-positive people screened for TB	1 114 394	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(88)	1 243 905
Previously treated cases, excluding relapse, registered in 2013	(66)	171 712
HIV-positive TB cases, all types, registered in 2013	(76)	44 027
RR-/MDR-TB cases started on second-line treatment in 2012	(46)	9 874
XDR-TB cases started on second-line treatment in 2012	(33)	91

## Laboratories 2014

Smear (per 100 000 population)	1.0
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	121
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	261
% Funded domestically	46%
% Funded internationally	54%
% Unfunded	0%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	100 (66–150)	41 (26–59)
Mortality (HIV+TB only)	22 (13–32)	8.5 (5.2–13)
Prevalence (includes HIV+TB) <sup>b</sup>	1 600 (1 300–2 000)	647 (513–797)
Incidence (includes HIV+TB)	1 000 (700–1 400)	399 (274–546)
Incidence (HIV+TB only)	63 (41–90)	25 (16–36)
Case detection, all forms (%)	32 (23–46)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.9 (1.4–2.5)	12 (8.1–17)
MDR-TB cases among notified pulmonary TB cases	5 600 (4 200–7 400)	1 100 (770–1 600)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	193 321	6 449
Pulmonary, clinically diagnosed	101 991	1 391
Extrapulmonary	19 653	1

**Total new and relapse** **322 806**

Previously treated, excluding relapses 1 733

**Total cases notified** **324 539**

Among 322 806 new and relapse cases:  
23 170 (7%) cases aged under 15 years; male:female ratio: 1.4

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	1 058 (<1%)	8 445 (88%)	9 503
Laboratory-confirmed RR-/MDR-TB cases			1 812
Patients started on MDR-TB treatment <sup>d</sup>			1 284

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	15 074	(5)
HIV-positive TB patients	2 355	(16)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	963	(41)
HIV-positive TB patients on antiretroviral therapy (ART)	624	(26)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(88)	325 582
Previously treated cases, excluding relapse, registered in 2013	(64)	1 521
HIV-positive TB cases, all types, registered in 2013	(49)	2 438
RR-/MDR-TB cases started on second-line treatment in 2012	(54)	432
XDR-TB cases started on second-line treatment in 2012	(64)	11

## Laboratories 2014

Smear (per 100 000 population)	2.2
Culture (per 5 million population)	0.4
Drug susceptibility testing (per 5 million population)	0.3
Sites performing Xpert MTB/RIF	41
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015

National TB programme budget (US\$ millions)	133
% Funded domestically	13%
% Funded internationally	21%
% Unfunded	66%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> The prevalence rate of bacteriologically confirmed TB was 531 (421–655) per 100 000 population; the prevalence rate of clinically diagnosed TB (i.e. smear-negative and culture-negative TB, including all extra-pulmonary cases) was 116 (91–143) per 100 000 population; the prevalence rate of extra-pulmonary TB (a subset of those in the clinically diagnosed category) was 58 (43–75) per 100 000 population.

<sup>c</sup> Includes cases with unknown previous TB treatment history.

<sup>d</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	9.4 (6.7–12)	21 (15–28)
Mortality (HIV+TB only)	8.1 (6.4–10)	18 (14–22)
Prevalence (includes HIV+TB)	120 (64–190)	266 (142–427)
Incidence (includes HIV+TB)	110 (110–110)	246 (240–252)
Incidence (HIV+TB only)	40 (38–42)	89 (84–93)
Case detection, all forms (%)	80 (78–82)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.2 (0.3–4.1)	14 (12–15)
MDR-TB cases among notified pulmonary TB cases	1 400 (200–2 700)	1 100 (930–1 200)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	34 997	3 569
Pulmonary, clinically diagnosed	30 872	2 947
Extrapulmonary	14 640	1 000

**Total new and relapse** 88 025

Previously treated, excluding relapses 1 269

**Total cases notified** 89 294

Among 89 294 new and relapse cases:

8 448 (9%) cases aged under 15 years; male:female ratio: 1.5

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	17 619 (50%)	7 436 (85%)	23 865
Laboratory-confirmed RR-/MDR-TB cases			644
Patients started on MDR-TB treatment <sup>c</sup>			544

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	84 423	(95)
HIV-positive TB patients	30 002	(36)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	29 735	(99)
HIV-positive TB patients on antiretroviral therapy (ART)	26 142	(87)
HIV-positive people screened for TB	426 102	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(86)	81 255
Previously treated cases registered in 2013	(78)	8 445
HIV-positive TB cases, all types, registered in 2013	(79)	31 755
RR-/MDR-TB cases started on second-line treatment in 2012	(83)	197
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	4.3
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.3
Sites performing Xpert MTB/RIF	70
Is second-line drug susceptibility testing available?	No

## Financing TB control 2015







National TB programme budget (US\$ millions)	45
% Funded domestically	26%
% Funded internationally	28%
% Unfunded	45%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Mozambique ■ Population 2014 27 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	18 (12–26)	67 (44–96)
Mortality (HIV+TB only)	37 (29–45)	134 (106–165)
Prevalence (includes HIV+TB)	150 (80–240)	554 (295–893)
Incidence (includes HIV+TB)	150 (120–180)	551 (435–680)
Incidence (HIV+TB only)	85 (65–110)	311 (237–395)
Case detection, all forms (%)	39 (31–49)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	3.5 (2.2–4.8)	11 (0–25)
MDR-TB cases among notified pulmonary TB cases	1 700 (1 100–2 300)	460 (0–1 000)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	24 430	1 542
Pulmonary, clinically diagnosed	23 455	2 070
Extrapulmonary	6 276	

**Total new and relapse** 57 773

Previously treated, excluding relapses 497

**Total cases notified** 58 270

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	886 (4%)	906 (22%)	3 716
Laboratory-confirmed RR-/MDR-TB cases			544
Patients started on MDR-TB treatment <sup>c</sup>			482

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	55 943	(96)
HIV-positive TB patients	29 337	(52)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	27 504	(94)
HIV-positive TB patients on antiretroviral therapy (ART)	23 801	(81)
HIV-positive people screened for TB	563 377	
HIV-positive people provided with IPT	94 252	

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013 <sup>d</sup>	(88)	23 072
Previously treated cases registered in 2013		
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(28)	214
XDR-TB cases started on second-line treatment in 2012	(0)	4

## Laboratories 2014

Smear (per 100 000 population)	1.2
Culture (per 5 million population)	0.6
Drug susceptibility testing (per 5 million population)	0.4
Sites performing Xpert MTB/RIF	24
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015

National TB programme budget (US\$ millions)	29
% Funded domestically	6%
% Funded internationally	66%
% Unfunded	28%







Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

<sup>d</sup> Treatment outcomes were available for new pulmonary bacteriologically confirmed cases only.



# Myanmar ■ Population 2014 53 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	28 (20–37)	53 (38–70)
Mortality (HIV+TB only)	4.1 (3.3–5.1)	7.7 (6.1–9.5)
Prevalence (includes HIV+TB)	240 (190–310)	457 (352–575)
Incidence (includes HIV+TB)	200 (180–220)	369 (334–406)
Incidence (HIV+TB only)	19 (15–24)	36 (28–44)
Case detection, all forms (%)	70 (64–78)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	5 (3.1–6.8)	27 (15–39)
MDR-TB cases among notified pulmonary TB cases	5 600 (3 500–7 700)	3 400 (1 900–4 900)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	42 608	5 276
Pulmonary, clinically diagnosed	70 305	3 650
Extrapulmonary	16 108	405

<b>Total new and relapse</b>	<b>138 352</b>
Previously treated, excluding relapses	3 605
<b>Total cases notified</b>	<b>141 957</b>

Among 138 352 new and relapse cases:  
36 301 (26%) cases aged under 15 years; male:female ratio: 1.6

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	10 295 (24%)	15 166 (117%)	26 240
Laboratory-confirmed RR-/MDR-TB cases			3 495
Patients started on MDR-TB treatment <sup>c</sup>			1 537

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	56 133	(40)
HIV-positive TB patients	6 412	(11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	4 666	(73)
HIV-positive TB patients on antiretroviral therapy (ART)	5 749	(90)
HIV-positive people screened for TB	54 178	
HIV-positive people provided with IPT	2 997	

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(87)	135 614
Previously treated cases registered in 2013	(71)	7 147
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(79)	443
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	0.9
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	38
Is second-line drug susceptibility testing available?	Yes, outside country

## Financing TB control 2015







National TB programme budget (US\$ millions)	36
% Funded domestically	11%
% Funded internationally	67%
% Unfunded	22%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.





# Nigeria ■ Population 2014 177 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	170 (91–280)	97 (51–156)
Mortality (HIV+TB only)	78 (53–110)	44 (30–61)
Prevalence (includes HIV+TB)	590 (450–740)	330 (253–417)
Incidence (includes HIV+TB)	570 (340–870)	322 (189–488)
Incidence (HIV+TB only)	100 (59–160)	59 (33–92)
Case detection, all forms (%)	15 (10–26)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.9 (2.1–4)	14 (10–19)
MDR-TB cases among notified pulmonary TB cases	2 300 (1 700–3 200)	1 000 (750–1 400)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	49 825	2 415
Pulmonary, clinically diagnosed	29 460	
Extrapulmonary	4 764	0

**Total new and relapse 86 464**

Previously treated, excluding relapses 4 890

**Total cases notified 91 354**

Among 91 354 new and relapse cases:

5 463 (6%) cases aged under 15 years; male:female ratio: 1.5

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			24 225
Laboratory-confirmed RR-/MDR-TB cases			798
Patients started on MDR-TB treatment <sup>c</sup>			423

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	84 161	(92)
HIV-positive TB patients	16 066	(19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	14 569	(91)
HIV-positive TB patients on antiretroviral therapy (ART)	11 997	(75)
HIV-positive people screened for TB	335 357	
HIV-positive people provided with IPT	26 383	

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(86)	91 997
Previously treated cases registered in 2013	(83)	8 404
HIV-positive TB cases, all types, registered in 2013	(80)	7 481
RR-/MDR-TB cases started on second-line treatment in 2012	(62)	154
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	1.0
Culture (per 5 million population)	0.2
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	96
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	228
% Funded domestically	13%
% Funded internationally	19%
% Unfunded	68%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	48 (11–110)	26 (6–61)
Mortality (HIV+TB only)	1.3 (0.76–1.9)	0.68 (0.41–1)
Prevalence (includes HIV+TB)	630 (530–740)	341 (285–402)
Incidence (includes HIV+TB)	500 (370–650)	270 (201–350)
Incidence (HIV+TB only)	6.4 (4.4–8.7)	3.4 (2.4–4.7)
Case detection, all forms (%)	62 (48–83)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	3.7 (2.5–5)	18 (13–23)
MDR-TB cases among notified pulmonary TB cases	9 000 (6 100–12 000)	2 900 (2 100–3 700)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	122 537	7 420
Pulmonary, clinically diagnosed	120 350	426
Extrapulmonary	57 463	221

## Total new and relapse

308 417

Previously treated, excluding relapses 8 160

## Total cases notified

316 577

Among 308 417 new and relapse cases:  
27 245 (9%) cases aged under 15 years; male:female ratio: 1.0

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	361 (<1%)	11 685 (72%)	20 143
Laboratory-confirmed RR-/MDR-TB cases			3 243
Patients started on MDR-TB treatment <sup>c</sup>			2 662

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	10 715	(3)
HIV-positive TB patients	90	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	90	(100)
HIV-positive TB patients on antiretroviral therapy (ART)	90	(100)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(93)	289 376
Previously treated cases, excluding relapse, registered in 2013	(80)	7 217
HIV-positive TB cases, all types, registered in 2013	(81)	37
RR-/MDR-TB cases started on second-line treatment in 2012	(71)	858
XDR-TB cases started on second-line treatment in 2012	(32)	41

## Laboratories 2014

Smear (per 100 000 population)	0.8
Culture (per 5 million population)	0.3
Drug susceptibility testing (per 5 million population)	0.1
Sites performing Xpert MTB/RIF	42
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	50
% Funded domestically	17%
% Funded internationally	60%
% Unfunded	23%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.





# Philippines ■ Population 2014 99 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	10 (9–11)	10 (9.1–11)
Mortality (HIV+TB only)	0.08 (0.055–0.11)	0.08 (0.06–0.11)
Prevalence (includes HIV+TB)	410 (360–470)	417 (367–471)
Incidence (includes HIV+TB)	290 (250–320)	288 (254–324)
Incidence (HIV+TB only)	2.5 (2–3.2)	2.6 (2–3.2)
Case detection, all forms (%)	85 (76–97)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2 (1.4–2.7)	21 (16–29)
MDR-TB cases among notified pulmonary TB cases	4 600 (3 300–6 300)	6 500 (4 700–8 700)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	92 991	6 277
Pulmonary, clinically diagnosed	139 950	
Extrapulmonary	4 161	

**Total new and relapse** 243 379

Previously treated, excluding relapses 24 057

**Total cases notified** 267 436

Among 97 578 new and relapse cases:

12 191 (12%) cases aged under 15 years; male:female ratio: 1.8

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	4 415 (5%)	20 196 (67%)	27 287
Laboratory-confirmed RR-/MDR-TB cases			3 000
Patients started on MDR-TB treatment <sup>c</sup>			2 680

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	53 354	(20)
HIV-positive TB patients	108	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	20	(19)
HIV-positive TB patients on antiretroviral therapy (ART)	53	(49)
HIV-positive people screened for TB	5 995	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(90)	216 250
Previously treated cases, excluding relapse, registered in 2013	(86)	2 924
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(43)	1 798
XDR-TB cases started on second-line treatment in 2012	(10)	10

## Laboratories 2014

Smear (per 100 000 population)	2.6
Culture (per 5 million population)	1.1
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	84
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	106
% Funded domestically	23%
% Funded internationally	39%
% Unfunded	37%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>b</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	16 (15–16)	11 (11–11)
Mortality (HIV+TB only)	1.1 (0.83–1.3)	0.73 (0.58–0.91)
Prevalence (includes HIV+TB)	160 (70–270)	109 (49–192)
Incidence (includes HIV+TB)	120 (110–130)	84 (76–93)
Incidence (HIV+TB only)	5.5 (4.5–6.6)	3.8 (3.1–4.6)
Case detection, all forms (%)	85 (77–94)	

## Estimates of MDR-TB burden<sup>b</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	19 (14–25)	49 (40–59)
MDR-TB cases among notified pulmonary TB cases	15 000 (11 000–19 000)	24 000 (19 000–29 000)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	37 296	7 982
Pulmonary, clinically diagnosed	40 894	6 753
Extrapulmonary	8 763	652

<b>Total new and relapse</b>	<b>102 340</b>
Previously treated, excluding relapses	33 828
<b>Total cases notified</b>	<b>136 168</b>

Among 102 340 new and relapse cases:  
3 195 (3%) cases aged under 15 years; male:female ratio: 2.3

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	31 250 (84%)	13 925 (28%)	45 175
Laboratory-confirmed RR-/MDR-TB cases			15 585
Patients started on MDR-TB treatment <sup>d</sup>			21 904

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status <sup>e</sup>	67 425	
HIV-positive TB patients	5 251	
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)		
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(68)	83 301
Previously treated cases, excluding relapse, registered in 2013	(39)	6 934
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(40)	16 021
XDR-TB cases started on second-line treatment in 2012	(26)	1 318

## Laboratories 2014

Smear (per 100 000 population)	3.7
Culture (per 5 million population)	14.1
Drug susceptibility testing (per 5 million population)	10.4
Sites performing Xpert MTB/RIF	96
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015

National TB programme budget (US\$ millions)	1 894
% Funded domestically	100%
% Funded internationally	<1%
% Unfunded	0%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.







<sup>a</sup> UN Population Division estimates are lower than the population registered by the Federal State Statistics Service of the Russian Federation.

<sup>b</sup> Ranges represent uncertainty intervals.

<sup>c</sup> Includes cases with unknown previous TB treatment history.

<sup>d</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

<sup>e</sup> The reported number of TB patients with known HIV status is for new TB patients in the civilian sector only. It was not possible to calculate the percentage of all TB patients with known HIV status.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	24 (22–26)	44 (41–48)
Mortality (HIV+TB only)	72 (58–89)	134 (107–164)
Prevalence (includes HIV+TB)	380 (210–590)	696 (390–1 088)
Incidence (includes HIV+TB)	450 (400–510)	834 (737–936)
Incidence (HIV+TB only)	270 (240–310)	509 (439–584)
Case detection, all forms (%)	68 (61–77)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.8 (1.4–2.3)	6.7 (5.4–8.2)
MDR-TB cases among notified pulmonary TB cases	4 700 (3 700–5 900)	1 500 (1 200–1 800)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	155 473	7 430
Pulmonary, clinically diagnosed	106 482	2 693
Extrapulmonary	33 522	566

<b>Total new and relapse</b>	<b>306 166</b>
Previously treated, excluding relapses	12 027
<b>Total cases notified</b>	<b>318 193</b>

Among 306 166 new and relapse cases:  
31 977 (10%) cases aged under 15 years; male:female ratio: 1.3

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB			218 231
Laboratory-confirmed RR-/MDR-TB cases			18 734
Patients started on MDR-TB treatment <sup>c</sup>			11 538

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	295 136	(93)
HIV-positive TB patients	179 756	(61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	155 017	(86)
HIV-positive TB patients on antiretroviral therapy (ART)	141 755	(79)
HIV-positive people screened for TB	1 148 477	
HIV-positive people provided with IPT	551 787	

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(78)	321 087
Previously treated cases, excluding relapse, registered in 2013	(69)	18 292
HIV-positive TB cases, all types, registered in 2013	(76)	191 189
RR-/MDR-TB cases started on second-line treatment in 2012	(49)	8 084
XDR-TB cases started on second-line treatment in 2012	(20)	607

## Laboratories 2014

Smear (per 100 000 population)	0.4
Culture (per 5 million population)	1.1
Drug susceptibility testing (per 5 million population)	1.1
Sites performing Xpert MTB/RIF	207
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	248
% Funded domestically	84%
% Funded internationally	8%
% Unfunded	8%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Thailand ■ Population 2014 68 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	7.4 (3.9–12)	11 (5.7–18)
Mortality (HIV+TB only)	4.5 (2.3–7.4)	6.6 (3.4–11)
Prevalence (includes HIV+TB)	160 (110–220)	236 (161–326)
Incidence (includes HIV+TB)	120 (61–190)	171 (90–276)
Incidence (HIV+TB only)	15 (7.8–24)	22 (12–36)
Case detection, all forms (%)	59 (36–110)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2 (1.4–2.8)	19 (14–25)
MDR-TB cases among notified pulmonary TB cases	1 100 (780–1 600)	1 100 (800–1 500)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	34 394	1 969
Pulmonary, clinically diagnosed	21 115	0
Extrapulmonary	10 244	0

<b>Total new and relapse</b>	<b>67 722</b>
Previously treated, excluding relapses	3 896
<b>Total cases notified</b>	<b>71 618</b>

Among 34 394 new cases:  
119 (<1%) cases aged under 15 years; male:female ratio: 2.5

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	4 370 (13%)	2 209 (38%)	9 580
Laboratory-confirmed RR-/MDR-TB cases			506
Patients started on MDR-TB treatment <sup>c</sup>			

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	50 670	(71)
HIV-positive TB patients	6 831	(13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	4 359	(64)
HIV-positive TB patients on antiretroviral therapy (ART)	4 691	(69)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(81)	65 867
Previously treated cases, excluding relapse, registered in 2013	(66)	1 812
HIV-positive TB cases, all types, registered in 2013	(67)	7 665
RR-/MDR-TB cases started on second-line treatment in 2012		
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	1.3
Culture (per 5 million population)	3.9
Drug susceptibility testing (per 5 million population)	1.5
Sites performing Xpert MTB/RIF	14
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	32
% Funded domestically	52%
% Funded internationally	11%
% Unfunded	37%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	4.5 (3.2–6.1)	12 (8.4–16)
Mortality (HIV+TB only)	6.4 (5–8.1)	17 (13–21)
Prevalence (includes HIV+TB)	60 (33–95)	159 (87–253)
Incidence (includes HIV+TB)	61 (53–69)	161 (141–183)
Incidence (HIV+TB only)	28 (24–32)	73 (63–84)
Case detection, all forms (%)	72 (64–83)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.4 (0.6–2.2)	12 (6.8–19)
MDR-TB cases among notified pulmonary TB cases	530 (230–830)	480 (270–770)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	26 079	1 499
Pulmonary, clinically diagnosed	11 854	468
Extrapulmonary	4 180	107

<b>Total new and relapse</b>	<b>44 187</b>
Previously treated, excluding relapses	1 984
<b>Total cases notified</b>	<b>46 171</b>

Among 44 187 new and relapse cases:  
3 316 (8%) cases aged under 15 years; male:female ratio: 1.8

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	1 958 (8%)	737 (18%)	3 569
Laboratory-confirmed RR-/MDR-TB cases			255
Patients started on MDR-TB treatment <sup>c</sup>			213

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	43 883	(95)
HIV-positive TB patients	19 612	(45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	19 211	(98)
HIV-positive TB patients on antiretroviral therapy (ART)	15 877	(81)
HIV-positive people screened for TB	729 268	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(75)	44 605
Previously treated cases, excluding relapse, registered in 2013	(67)	2 572
HIV-positive TB cases, all types, registered in 2013	(73)	16 762
RR-/MDR-TB cases started on second-line treatment in 2012	(80)	41
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	3.6
Culture (per 5 million population)	0.7
Drug susceptibility testing (per 5 million population)	0.7
Sites performing Xpert MTB/RIF	74
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	24
% Funded domestically	10%
% Funded internationally	69%
% Unfunded	21%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	30 (13–54)	58 (26–104)
Mortality (HIV+TB only)	28 (15–43)	53 (30–84)
Prevalence (includes HIV+TB)	270 (110–510)	528 (215–979)
Incidence (includes HIV+TB)	170 (80–290)	327 (155–561)
Incidence (HIV+TB only)	62 (29–110)	120 (56–208)
Case detection, all forms (%)	36 (21–77)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	1.1 (0.5–2)	3.1 (0.9–7.9)
MDR-TB cases among notified pulmonary TB cases	520 (230–940)	80 (23–200)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	23 583	1 008
Pulmonary, clinically diagnosed	23 380	
Extrapulmonary	13 600	

<b>Total new and relapse</b>	<b>61 571</b>
Previously treated, excluding relapses	1 580
<b>Total cases notified</b>	<b>63 151</b>

Among 61 571 new and relapse cases:  
6 463 (10%) cases aged under 15 years; male:female ratio: 1.5

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	9 506 (40%)	882 (34%)	35 923
Laboratory-confirmed RR-/MDR-TB cases			516
Patients started on MDR-TB treatment <sup>c</sup>			143

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	57 612	(91)
HIV-positive TB patients	20 055	(35)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	19 388	(97)
HIV-positive TB patients on antiretroviral therapy (ART)	16 564	(83)
HIV-positive people screened for TB	525 713	
HIV-positive people provided with IPT	23 124	

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(91)	64 053
Previously treated cases, excluding relapse, registered in 2013	(79)	1 679
HIV-positive TB cases, all types, registered in 2013	(72)	20 320
RR-/MDR-TB cases started on second-line treatment in 2012	(73)	45
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	1.8
Culture (per 5 million population)	0.4
Drug susceptibility testing (per 5 million population)	<0.1
Sites performing Xpert MTB/RIF	59
Is second-line drug susceptibility testing available?	Yes, in country

## Financing TB control 2015







National TB programme budget (US\$ millions)	67
% Funded domestically	
% Funded internationally	
% Unfunded	100%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.





# Viet Nam ■ Population 2014 **92 million**

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	17 (11–23)	18 (12–25)
Mortality (HIV+TB only)	1.9 (1.3–2.5)	2 (1.4–2.7)
Prevalence (includes HIV+TB)	180 (76–330)	198 (83–362)
Incidence (includes HIV+TB)	130 (110–150)	140 (116–167)
Incidence (HIV+TB only)	7 (5.7–8.5)	7.6 (6.1–9.2)
Case detection, all forms (%)	77 (65–94)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	4 (2.5–5.4)	23 (17–30)
MDR-TB cases among notified pulmonary TB cases	3 000 (1 900–4 100)	2 100 (1 500–2 600)

## TB case notifications 2014

	NEW <sup>c</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	49 938	7 114
Pulmonary, clinically diagnosed	25 179	
Extrapulmonary	18 118	

<b>Total new and relapse</b>	<b>100 349</b>
Previously treated, excluding relapses	1 738
<b>Total cases notified</b>	<b>102 087</b>

Among 49 929 new cases:  
144 (<1%) cases aged under 15 years; male:female ratio: 3.0

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	2 756 (6%)	8 511 (96%)	13 829
Laboratory-confirmed RR-/MDR-TB cases			2 198
Patients started on MDR-TB treatment <sup>c</sup>			1 532

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	74 092	(73)
HIV-positive TB patients	3 875	(5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	2 936	(76)
HIV-positive TB patients on antiretroviral therapy (ART)	2 827	(73)
HIV-positive people screened for TB	90 592	
HIV-positive people provided with IPT		

## Treatment success rate and cohort size

	(%)	COHORT
New and relapse cases registered in 2013	(89)	102 196
Previously treated cases, excluding relapse, registered in 2013		
HIV-positive TB cases, all types, registered in 2013	(71)	4 453
RR-/MDR-TB cases started on second-line treatment in 2012	(71)	713
XDR-TB cases started on second-line treatment in 2012		0

## Laboratories 2014

Smear (per 100 000 population)	1.1
Culture (per 5 million population)	1.2
Drug susceptibility testing (per 5 million population)	0.1
Sites performing Xpert MTB/RIF	30
Is second-line drug susceptibility testing available?	Yes, in and outside country

## Financing TB control 2015







National TB programme budget (US\$ millions)	66
% Funded domestically	10%
% Funded internationally	17%
% Unfunded	72%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.



# Zimbabwe ■ Population 2014 15 million

## Estimates of TB burden<sup>a</sup> 2014

	NUMBER (thousands)	RATE (per 100 000 population)
Mortality (excludes HIV+TB)	2.3 (1.4–3.4)	15 (9.5–22)
Mortality (HIV+TB only)	5.2 (3.2–7.8)	34 (21–51)
Prevalence (includes HIV+TB)	44 (24–71)	292 (158–465)
Incidence (includes HIV+TB)	42 (29–58)	278 (193–379)
Incidence (HIV+TB only)	25 (17–35)	167 (114–229)
Case detection, all forms (%)	70 (51–100)	

## Estimates of MDR-TB burden<sup>a</sup> 2014

	NEW	RETREATMENT
% of TB cases with MDR-TB	2.2 (0.3–4.1)	11 (6.2–16)
MDR-TB cases among notified pulmonary TB cases	540 (73–1 000)	410 (230–590)

## TB case notifications 2014

	NEW <sup>b</sup>	RELAPSE
Pulmonary, bacteriologically confirmed	11 224	1 369
Pulmonary, clinically diagnosed	13 151	
Extrapulmonary	3 909	

<b>Total new and relapse</b>	<b>29 653</b>
Previously treated, excluding relapses	2 363
<b>Total cases notified</b>	<b>32 016</b>

Among 29 653 new and relapse cases:  
2 290 (8%) cases aged under 15 years; male:female ratio: 1.3

## Reported cases of RR-/MDR-TB 2014

	NEW	RETREATMENT	TOTAL <sup>b</sup>
Cases tested for RR-/MDR-TB	341 (3%)	237 (6%)	7 585
Laboratory-confirmed RR-/MDR-TB cases			412
Patients started on MDR-TB treatment <sup>c</sup>			381

## TB/HIV 2014

	NUMBER	(%)
TB patients with known HIV status	28 508	(89)
HIV-positive TB patients	19 290	(68)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	18 200	(94)
HIV-positive TB patients on antiretroviral therapy (ART)	16 522	(86)
HIV-positive people screened for TB	133 997	
HIV-positive people provided with IPT	30 420	

## Treatment success rate and cohort size

	(%)	COHORT
New cases registered in 2013	(80)	35 278
Previously treated cases registered in 2013		
HIV-positive TB cases, all types, registered in 2013		
RR-/MDR-TB cases started on second-line treatment in 2012	(75)	234
XDR-TB cases started on second-line treatment in 2012		

## Laboratories 2014

Smear (per 100 000 population)	1.4
Culture (per 5 million population)	0.7
Drug susceptibility testing (per 5 million population)	0.7
Sites performing Xpert MTB/RIF	62
Is second-line drug susceptibility testing available?	Yes, in and outside country

## Financing TB control 2015

National TB programme budget (US\$ millions)	28
% Funded domestically	7%
% Funded internationally	59%
% Unfunded	34%

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.

<sup>b</sup> Includes cases with unknown previous TB treatment history.

<sup>c</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

